At a glance
- Originator GlaxoSmithKline
- Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bipolar disorders; Epilepsy
Most Recent Events
- 07 Dec 2001 Discontinued-II for Bipolar disorders (Unknown route)
- 07 Dec 2001 Discontinued-II for Epilepsy (Unknown route)
- 18 Apr 2001 Phase-II clinical trials for Bipolar disorders (Unknown route)